Swedish medical company OssDsign AB (publ) reported on Friday the receipt of US Food and Drug Administration (FDA) 510(k) clearance (K190523) to market its Cranial PSI Accessories in the US.
The company said the Cranial PSI Accessories cleared products are a set of 3D-printed, patient specific accessory devices designed to support and expand clinical use of its patient specific cranioplasty implant already cleared by the FDA. The accessories are designed to make cranial reconstructions safer and easier and to enable new solutions for patients in need of complex cranial reconstructions.
Under its market expansion plans, the company has developed anatomical models, surgical guides and intraoperative implant trials. The accessories are designed to make cranial reconstructions safer, easier and enable new solutions for complex cranial reconstructions.
Following the US FDA clearance, the new accessories, along with the company's novel implant technology, will provide US neurosurgeons the possibility to remove bone tumors or otherwise diseased bony tissue and perform cranial reconstruction in a single stage procedure.
In conjunction, the company's Cranial PSI Accessories have already been available on the European market and European neurosurgeons have successfully been able to treat patients for whom no viable surgical solution previously existed.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT